About Waterley Pharma
Committed to help people feel healthier and live a longer life.
ABOUT US
Located in the vibrant city of Hyderabad, India, Waterley Pharmaceuticals is an industry-leading pharmaceutical company. Our exceptional team of dynamic professionals brings together a wealth of experience garnered over many years in the pharmaceutical field.
Recognizing the urgent demand for innovative medical solutions, we are committed to making a positive impact on the lives of millions of individuals. Our primary focus lies in advancing gastro-intestinal therapy, catering to the specific needs of patients in this area.
At Waterley Pharmaceuticals, our ultimate objective is to improve the well-being of people globally by providing effective and groundbreaking pharmaceutical treatments.
OVERVIEW
Gastrointestinal diseases in Asian populations have been a major health issue during the past two decades. The incidence and prevalence rates have shown a notable rise, with the consequence that GI diseases are increasingly the cause of morbidity and mortality in Asian countries.
In the present scenario, while diseases like diarrhoeas, hepatitis, typhoid, TB of the intestinal tract etc. are still prevalent, there is an alarming is the rise of lifestyle diseases like Irritable Bowel syndrome (IBS), Gastroesophageal reflux disease (GERD), inflammatory bowel disease like Crohn’s and non-alcoholic fatty liver and cancers of the food pipe, colon and liver, pancreas and gallbladder.
Waterley Pharmaceuticals sees opportunities in this growing gastrointestinal therapy segment in India and neighbouring Asian countries. The company markets innovative, high quality medications to meet the evolving challenges and unmet needs of patients.
MILESTONES
2014
Incorporation of Waterley Pharmaceuticals.
2016
Market Expansion in North Eastern States, India.
2018
New Brands launched – Megaley (Omega 3 acid ethyl esters), Megaley-E (Omega 3 FA + Vit E). Rematin IBD – Specialized nutritional supplement for Inflammatory Bowel Disease and Hepsure (BCAA’s).
2021
Launch of Aladrine (Midodrine Hcl) a potent vasopressor and Betadek – a combination of fat-soluble vitamins.
2015
Evir (Entecavir), an antiviral for Hepatitis B and Hepkart (Ademetionine) a hepatoprotective launched successfully.
2017
Launch of brands Mycolon (Mebeverine) for use in IBS & Cretox CP a high-dose antioxidant for pain relief in Chronic Pancreatitis. Expanded operations in Western & Southern India.
2019
Launched Bistas (CBS) for treating H.pylori infection and Dexolan (Dexlansoprazoloe MR) a new generation proton pump inhibitor.
2022
Launched Rematin Plus Peptide powder – specialized nutrition for patients with G.I. Intolerance.
2014
Incorporation of Waterley Pharmaceuticals.
2015
Evir (Entecavir) an antiviral for Hepatitis B and Hepkart (Ademetionine) a hepatoprotective, launched successfully.
2016
Market Expansion in North Eastern States, India.
2017
Launch of Mycolon (Mebeverine) for use in IBS & Cretox CP, a high-dose antioxidant for pain relief in Chronic Pancreatitis. Expanded operations in Western & Southern India.
2018
New brands launched – Megaley (Omega-3 acid ethyl esters), Megaley E (Omega-3 FA+Vit E), Rematin IBD – Specialized nutritional supplement for IBD and Hepsure (BCAA’s).
2021
Launch of Aladrine (Midodrine Hcl) – a potent vasopressor and Betadek – a combination of fat-soluble vitamins.
2019
Launched Bistas (CBS) – for the treatment of H.pylori infection, and Dexolan (Dexlansoprazole MR) – a new generation PPI.
2022
Launch of Rematin Plus Peptide Powder – specialzied nutrition for patients with G.I. Intolerance.
MANAGEMENT
The leadership at Waterley Pharmaceuticals is led by a diverse, dynamic, committed and entrepreneurial team and are experienced professionals with a deep understanding of science and healthcare. We are passionate about developing innovative solutions that improve the lives of patients.
Directors (left to right): Mr. Megham Reddy, Mr. Ganesh Kumar, Mr. Venugopal Reddy, Mr. Manish Sutrave, Mr. K.P. Shinod.